Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 238

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 238
---
 in a DNA sample that include treating the sample to encode the presence or absence of DNA methylation, adding to the sample a set of                                           
 synthetic molecules (e.g., quality control template (QCT) molecules), generating a co-amplification mixture, sequencing the co-amplification mixture, and determining a                                        
 number of methylated molecules in the sample based on the number of methylated reads from the sample and a number of reads from the set of synthetic molecules.                                                |     |  12,043,873 |     | 3-21-2043 |     | Pending: AU, CA, CN, EU, JP, KR |
| P10    |     | Non-Invasive Prenatal Testing at Early Stage of Pregnancy              |     | A highly accurate non-invasive prenatal testing methodology that allows accurate fetal rhesus determination and fetal DNA fraction                                                                             
 measurement in a single assay is provided. The disclosed testing may be administered as early as at week 10 of pregnancy and can be conveniently combined with prenatal genetic disease testing and detection. |     |  11,946,104 |     | 7-7-2040  |     | Pending: CA, EU                 |

| BZ = Brazil      |     | CN = China                  |     | IR = Ireland       |     | PT = Portugal       |
| CA = Canada      |     | CY = Cyprus                 |     | IT = Italy         |     | SE = Sweden         |
| CH = Switzerland |     | DE = Germany                |     | LE = Liechtenstein |     | SG = Singapore      |
| DN = Denmark     |     | EU = European Union         |     | NL = Netherlands   |     | UK = United Kingdom |
| FR = France      
 IL = Isreal      |     | FN = Finland HK = Hong Kong 
 IN = India                  |     | NO = Norway        |     | PCT = Patent        
 Cooperation Treaty  |

To date, we have not been engaged in patent infringement lawsuits or any other material intellectual property disputes. However, we may in the future become subject to or initiate intellectual property litigation. Moreover, our ability to compete effectively depends to a large extent on our ability to develop proprietary products and technologies and to maintain adequate protection of our intellectual property in the United States and other countries. We pursue intellectual property protection to the extent we believe it would advance our business objectives. Notwithstanding these efforts, there can be no assurance that we will adequately protect our 174

intellectual